HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared with Novo Nordisk’s rival Wegovy pill.

By FiercePharma · May 1, 2026 · via FiercePharma
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
moneyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyDrug Channels ↗
Where Gross-to-net Pressure Actually Lives After Launch
Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. Cindy explains that many gro…
May 1, 2026
Analysts focus on three programs in big year for Bristol Myers
MoneyEndpoints News ↗
Analysts focus on three programs in big year for Bristol Myers
Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pit…
Apr 30, 2026
Avalyn’s $300M IPO Signals Renewed Appetite for Reformulation Plays
MoneyBriefing
Avalyn’s $300M IPO Signals Renewed Appetite for Reformulation Plays
Avalyn Pharma priced its Nasdaq debut at the top of range, raising $300M to push inhaled versions of existing …
Apr 30, 2026